HS-20093 in Patients With Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3,
a target wildly expressed on solid tumor cells. The objectives of this study are to
investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093
in Chinese advanced esophageal carcinoma and other solid tumor patients.